全文获取类型
收费全文 | 100084篇 |
免费 | 6257篇 |
国内免费 | 742篇 |
专业分类
耳鼻咽喉 | 1159篇 |
儿科学 | 3038篇 |
妇产科学 | 2491篇 |
基础医学 | 13263篇 |
口腔科学 | 2378篇 |
临床医学 | 7989篇 |
内科学 | 22112篇 |
皮肤病学 | 2144篇 |
神经病学 | 9232篇 |
特种医学 | 3817篇 |
外国民族医学 | 23篇 |
外科学 | 14398篇 |
综合类 | 1691篇 |
一般理论 | 48篇 |
预防医学 | 5909篇 |
眼科学 | 1639篇 |
药学 | 8060篇 |
3篇 | |
中国医学 | 532篇 |
肿瘤学 | 7157篇 |
出版年
2023年 | 425篇 |
2022年 | 1038篇 |
2021年 | 1888篇 |
2020年 | 1226篇 |
2019年 | 1765篇 |
2018年 | 2191篇 |
2017年 | 1667篇 |
2016年 | 1705篇 |
2015年 | 1985篇 |
2014年 | 2638篇 |
2013年 | 3800篇 |
2012年 | 5181篇 |
2011年 | 5329篇 |
2010年 | 3509篇 |
2009年 | 3062篇 |
2008年 | 4771篇 |
2007年 | 4911篇 |
2006年 | 4701篇 |
2005年 | 4518篇 |
2004年 | 4816篇 |
2003年 | 4641篇 |
2002年 | 4658篇 |
2001年 | 3830篇 |
2000年 | 3788篇 |
1999年 | 3079篇 |
1998年 | 1176篇 |
1997年 | 942篇 |
1996年 | 873篇 |
1995年 | 828篇 |
1994年 | 706篇 |
1993年 | 688篇 |
1992年 | 1844篇 |
1991年 | 1821篇 |
1990年 | 1538篇 |
1989年 | 1468篇 |
1988年 | 1361篇 |
1987年 | 1222篇 |
1986年 | 1205篇 |
1985年 | 1060篇 |
1984年 | 784篇 |
1983年 | 715篇 |
1982年 | 468篇 |
1981年 | 398篇 |
1979年 | 588篇 |
1978年 | 425篇 |
1975年 | 443篇 |
1974年 | 501篇 |
1973年 | 483篇 |
1972年 | 435篇 |
1971年 | 413篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
Although hepatitis E virus (HEV) is the primary cause of enterically transmitted acute hepatitis and jaundice in developing countries, locally acquired HEV infections are increasing in nonendemic countries. As such, HEV is emerging as an underdiagnosed cause of infection. This report describes three clinically variable cases of HEV infection with unusual clinical presentations. These cases highlight the fact that HEV should be considered in the differential diagnosis of patients with unexplained hepatitis (acute or chronic) with or without extrahepatic manifestations. HEV should also be considered in patients with persistently elevated liver enzymes who have not travelled to known HEV-endemic regions. Lack of knowledge among physicians and an absence of standardized diagnostic tests may result in increased morbidity and mortality from HEV infection. 相似文献
5.
Femoral access‐related complications during percutaneous transcatheter aortic valve implantation comparing single versus double Prostar XL device closure 下载免费PDF全文
6.
José A. Lorente Pablo Cardinal-Fernández Diego Muñoz Fernando Frutos-Vivar Arnaud W. Thille Carlos Jaramillo Aida Ballén-Barragán José M. Rodríguez Oscar Peñuelas Guillermo Ortiz José Blanco Bruno Valle Pinheiro Nicolás Nin María del Carmen Marin Andrés Esteban Taylor B. Thompson 《Intensive care medicine》2015,41(11):1921-1930
7.
8.
Miguel A. Sanz Pau Montesinos Haesook T. Kim Guillermo J. Ruiz-Argüelles María S. Undurraga María R. Uriarte Lem Martínez Rafael H. Jacomo Homero Gutiérrez-Aguirre Raul A. M. Melo Rosane Bittencourt Ricardo Pasquini Katia Pagnano Evandro M. Fagundes Edo Vellenga Alexandra Holowiecka Ana J. González-Huerta Pascual Fernández Javier De la Serna Salut Brunet Elena De Lisa José González-Campos José M. Ribera Isabel Krsnik Arnold Ganser Nancy Berliner Raul C. Ribeiro Francesco Lo-Coco Bob L?wenberg Eduardo M. Rego 《Annals of hematology》2015,94(8):1347-1356
9.
Marco Maruzzo Umberto Basso Eugenio Borsatti Laura Evangelista Filippo Alongi Orazio Caffo Francesca Maines Sara Galuppo Rocco De Vivo Fable Zustovich Dario Palleschi Andrea Zivi Teodoro Sava Mariella Sorarù Roberto Iacovelli Maurizio Nicodemo Susanne Baier Lucia Fratino Vittorina Zagonel 《Clinical genitourinary cancer》2019,17(1):e187-e194
Background
Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting.Patients and Methods
We conducted a multicenter retrospective analysis in the Triveneto region of Italy.Results
One hundred fifty-eight patients received radium 223 in our region. After a median follow-up of 9.5 months, 75 patients died. The median overall survival (OS) was 14.2 months, and the median progression-free survival (PFS) was 6.2 months. Seventy-one (45%) patients achieved progression as best response. Thirty-seven (23%) patients stopped the treatment early because of progression. Eastern Cooperative Oncology Group performance status was prognostic for OS (18.4 vs. 12.3 vs. 7.5 months; 0 vs. 1, P = .0062; 0 vs. 2, P = .0002), whereas previous prostatectomy or docetaxel exposure were not. A neutrophil to lymphocytes ratio ≥ 3 significantly impacted OS (18.1 vs. 9.7 months; P < .001) and slightly impacted PFS (6.6 vs. 5.6 months; P = .05). Patients with a baseline alkaline phosphatase (ALP) value ≥ 220 U/L had worse OS and PFS (24.1 vs. 10.5 months; 7.2 vs. 5.5 months; P < .001). Patients with changes in ALP value achieved better OS (P = .029) and PFS (P = .002). There was no difference according to the line of therapy (0 vs. ≥ 1; P = .490). The main grade 3/4 toxicities were anemia, asthenia, and thrombocytopenia.Conclusion
This large real-world report confirms comparable OS and PFS data when compared with the pivotal study, as well as the predictive role of ALP and neutrophil to lymphocytes ratio. The definition of the optimal position of radium 223 in the treatment of metastatic castration-resistant prostate cancer has still to be defined. 相似文献10.
Giorgio Gandaglia Guillaume Ploussard Massimo Valerio Agostino Mattei Cristian Fiori Nicola Fossati Armando Stabile Jean-Baptiste Beauval Bernard Malavaud Mathieu Roumiguié Daniele Robesti Paolo Dell’Oglio Marco Moschini Stefania Zamboni Arnas Rakauskas Francesco De Cobelli Francesco Porpiglia Francesco Montorsi Alberto Briganti 《European urology》2019,75(3):506-514